Results 101 to 110 of about 7,486 (163)

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study [PDF]

, 2013
Objective To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN). Methods Patients were randomized 1:1:1 to receive placebo, 400 mg ocrelizumab, or 1,000 mg ocrelizumab given as an intravenous infusion on
Richard A. Furie, Marc Bijl, Kajal Rao, Jayne, David, Renato Guzman, Alberto J. Spindler, Frédéric A. Houssiau, Shahdad, Saba, Paul Brunetta, Spindler, Alberto J., Mysler, Eduardo F., Bijl, Marc, Eduardo F. Mysler, Jorn Drappa, Furie, Richard A., Drappa, Jorn, Houssiau, Frédéric, Romeo Maciuca, David Jayne, David Close, MacIuca, Romeo, Saba Shahdad, Guzman, Renato, Close, David, Rao, Kajal, Brunetta, Paul   +25 more
core   +1 more source

Extended interval dosing with ocrelizumab in multiple sclerosis [PDF]

BACKGROUND: This study investigates clinical and biomarker differences between standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple sclerosis (MS).METHODS: This is a prospective, double-arm, open-label ...
Stilund, Morten Leif, Novak, Frederik; id_orcid, Novak, Frederik, Illes, Zsolt, Berg, Jonas Munksgaard, Urbonaviciute, Inga, Christensen, Jeppe Romme, Sellebjerg, Finn, Bajwa, Hamza Mahmood, Madsen, Jonna Skov, Sejbaek, Tobias; id_orcid, Østergaard, Kamilla, Sejbaek, Tobias, Romme Christensen, Jeppe, Olsen, Dorte Aalund, Bramow, Stephan   +15 more
core   +1 more source

Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients

Frontiers in Neurology
BackgroundWidespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world observation. Among these, drug-induced colitis is a rare,
Ileana Maria Vodă, Vlad Eugen Tiu, Vlad Eugen Tiu, Luiza Răuță, Paul Ciucur, Andreea Ioana Mușuroi, Alina Flavia Tomescu, Alina Flavia Tomescu, Nicoleta Laura Humă, Florin Dobrițoiu, Florin Dobrițoiu, Elena Terecoasă, Elena Terecoasă, Lucian Negreanu, Lucian Negreanu, Cristina Tiu, Cristina Tiu   +16 more
doaj   +1 more source

Safety and Efficacy of Fingolimod and Ocrelizumab in Pediatric Patients with Multiple Sclerosis

BACKGROUND: Fingolimod and ocrelizumab are approved treatments for adults with multiple sclerosis (MS); however, only fingolimod is FDA-approved for the treatment of pediatric MS.
Brenton, J. Nicholas, Spirek, Benton
core   +1 more source

Ocrelizumab in the treatment of multiple sclerosis: real-world clinical practice experience in the Yaroslavl region

Неврология, нейропсихиатрия, психосоматика
The most significant results in terms of efficacy in relapsing-remitting multiple sclerosis (MS) and primary progressive MS have been demonstrated for the drug ocrelizumab.
D. S. Kasatkin, E. V. Kiseleva, I. O. Stepanov, N. N. Spirina   +3 more
doaj   +1 more source

Ocrelizumab per al tractament de l'esclerosi múltiple en pacients adults [PDF]

, 2019
Ocrelizumab; Esclerosi múltiple; Pacients adultsOcrelizumab; Esclerosis múltiple; Pacientes adultosOcrelizumab; Multiple sclerosis; Adult patientsOcrelizumab és un anticòs monoclonal humanitzat que actua de forma selectiva contra limfòcits B que ...
Programa d'Harmonització Farmacoterapèutica
core  

BAFF is a marker of hypogammaglobulinemia, neuroaxonal damage and inflammation in multiple sclerosis patients on ocrelizumab

Journal of Neuroinflammation
Background and objectives Serum biomarker testing for multiple sclerosis has been increasing in popularity in research and clinical practice.
Anastasia Chumakova, Lauren McKay, Victoria Fleming, Michael Demetriou, Michael Sy   +4 more
doaj   +1 more source

Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).

, 2023
INTRODUCTION: Natalizumab is associated with a risk of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients infected with John Cunningham virus (JCV).
Gervasi-Follmar, Tiffany, Cohan, Stanley, Marginean, Horia, Repovic, Pavle, Smoot, Kyle, Chen, Chiayi   +5 more
core  

Ocrelizumab for treating relapsing multiple sclerosis

, 2018
This report is a critique of the company’s submission (CS) to NICE from Roche on the clinical effectiveness and cost effectiveness of ocrelizumab for relapsing forms of multiple sclerosis.
Lord, Joanne, Onyimadu, Oluchukwu, Harris, Petra B, Shepherd, Jonathan, Frampton, Geoffrey   +4 more
core   +1 more source

Disease Course, Outcomes, and Complications in Pregnant and Breastfeeding Women with Multiple Sclerosis Treated with Rituximab or Ocrelizumab: A Narrative Review. [PDF]

J Res Pharm Pract
Ashtari F, Momenzadeh M.
europepmc   +1 more source